Intrarectal Administration of Adelmidrol plus Hyaluronic Acid Gel Ameliorates Experimental Colitis in Mice and Inhibits Pro-Inflammatory Response in Ex Vivo Cultured Biopsies Derived from Ulcerative Colitis-Affected Patients
Laboratory studyHumansOther animalsWith adelmidrol (a PEA analogue) with hyaluronic acid, as a gel
This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue) with hyaluronic acid, as a gel. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with DNBS-induced colitis, plus cultured colon biopsies from ulcerative colitis patients in remission
- Dose used in the study
- 2% adelmidrol and 0.1% hyaluronic acid gel given intrarectally
- Duration
- Not stated in the abstract
- What was measured
- Histological damage score and tight junction proteins ZO-1 and occludin in mice and in human biopsies challenged with a cytokine mix
What the authors reported
The gel reduced the histological damage score and increased ZO-1 and occludin expression in both the mouse model and the human specimens. The authors describe the effect as a local antioxidant barrier effect, acting without noticeable systemic absorption and independently of endogenous PEA levels.
Limits of this study
A mouse model and ex vivo human tissue study; it cannot show effect in people treated in practice. Adelmidrol is an analogue, not palmitoylethanolamide. The abstract names Vessilen, a commercial adelmidrol product. The authors declare no conflicts of interest.
Source
PubMed 38203336 · doi:10.3390/ijms25010165
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.